ChordArt TMVr - System / Primary Mitral Regurgitation

FIRST LINE TREATMENT FOR MITRAL VALVE DISEASE

COREMEDIC GMBH

An innovative cardiology company

CoreMedic was initiated in 2012 as a spin-out in Bern, Switzerland, in order to develop an innovative treatment concept for mitral valve regurgitation (MR). The initiators of CoreMedic had a simple but challenging idea: to combine the least invasive treatment option for MR, replacement of mitral chords, and the least invasive operational procedure into one new system: ChordArt.

In 2014, CoreMedic became operational as an independent entity with own management and facilities.

In 2017, the development of ChordArt had progressed towards first use in a human trial, enabling CoreMedic to attract institutional financing. The company moved to RIZ-innovation center at Radolfzell, Germany, located at Lake Constance close to the Swiss border within the leading medical technology cluster of Tuttlingen, Germany.

Following successful conclusion of the first human trial of ChordArt in 2018, and five-year data confirming the powerful treatment effect of the ChordArt implant in patients with severe MR, CoreMedic GmbH is tirelessly working to make the ChordArt TMVr - System available to patients.

Fritz-Reichle-Ring 2, 78315 Radolfzell, Germany; Company HQ

IMPRESSUM
Company:CoreMedic GmbH
Address: Fritz-Reichle-Ring 2, 78315 Radolfzell, Germany
Authorized representative managing director: Thomas Bauer
Phone: +49 (0)7732 – 8934610
E-Mail: info@coremedic.de
Sales tax identification number according to § 27 a sales tax law: DE312592224
Register court: Freiburg i.Br.
Registration number: HR B 718890
Liability Notice
We assume no liability for the content of external links.
We expressly distance ourselves from their content and preparation and emphasize that we have no influence of any kind on the design and content of these links or any subsequent offers.